---
title: 'Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma:
  No Ordinary Subgroup Analysis'
date: '2023-10-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37797275/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231006180936&v=2.17.9.post6+86293ac
source: Blood
description: Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus
  chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among
  patients with activated B-cell subtype disease. Both preclinical and additional
  clinical evidence support this interaction between cell-of-origin and polatuzumab
  ...
disable_comments: true
---
Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab ...